ADVERTISEMENT
An artist’s rendering of a DNA-based virus trap, represented as gray rods in a short cone-shaped arrangement. One is coated with blue molecules, likely antibodies, that adhere to a virus target. Another image shows to traps coming together to capture a red coronavirus.
“Origami” DNA Traps Could Keep Large Viruses From Infecting Cells
By engineering structures out of DNA, scientists could potentially prevent larger viruses, like coronaviruses and influenza viruses, from interacting with cells.
“Origami” DNA Traps Could Keep Large Viruses From Infecting Cells
“Origami” DNA Traps Could Keep Large Viruses From Infecting Cells

By engineering structures out of DNA, scientists could potentially prevent larger viruses, like coronaviruses and influenza viruses, from interacting with cells.

By engineering structures out of DNA, scientists could potentially prevent larger viruses, like coronaviruses and influenza viruses, from interacting with cells.

antiviral therapy
Several silver foil pill packs with white pills
FDA Authorizes Pfizer’s Paxlovid, First Oral Therapy for COVID-19
Jef Akst | Dec 23, 2021 | 2 min read
Given within three days of symptom onset, the pill combination was nearly 90 percent effective at preventing high-risk patients from developing severe illness in a clinical study.
Updated
Merck research facility in San Francisco
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Chloe Tenn | Oct 1, 2021 | 3 min read
Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.
Fast-Tracking COVID-19 Research
The Scientist Creative Services Team in collaboration with Sartorius Corporation | 1 min read
Identifying molecular targets for SARS-CoV-2 therapeutics.
the molecular structure of interferon-alpha
Lots of Rapid Evolution in Interferon-Stimulated Genes: Study
Christie Wilcox, PhD | Jul 1, 2021 | 2 min read
A comparison of interferon-related genes across 20 primate genomes reveals differences in the speed at which they evolve and new targets for antiviral discovery efforts.
2020 in Scientists’ Own Words
Abby Olena, PhD | Dec 23, 2020 | 5 min read
The world was rocked by the COVID-19 pandemic this year, but researchers rose to all manner of challenges.
The Scientist Speaks Podcast - Episode 9
The Scientist Creative Services Team | 1 min read
Repurposing Living Systems to Fight a Pandemic
Researchers Who Discovered Hepatitis C Earn Nobel Prize
Max Kozlov | Oct 5, 2020 | 3 min read
Harvey Alter, Michael Houghton, and Charles Rice share the Physiology or Medicine award for their contributions to identifying the virus and demonstrating that it was responsible for hepatitis among blood transfusion recipients.
Gilead Urged to Explore Remdesivir Relative as COVID-19 Drug
Catherine Offord | Aug 11, 2020 | 2 min read
Citizen advocates push the pharmaceutical company to examine a compound that has been used to treat certain coronavirus infections in cats.
Combating COVID-19 with Cell-Free Expression
The Scientist Creative Services Team | 6 min read
Scientists rely on synthetic biology and cell-free expression systems for developing novel approaches to combat the pandemic.
AI Is Screening Billions of Molecules for Coronavirus Treatments
Abby Olena, PhD | May 7, 2020 | 6 min read
Machine learning has pegged existing drugs to repurpose for COVID-19 clinical trials.
Remdesivir Shows Promise in Largest of Several Clinical Trials
Catherine Offord | Apr 30, 2020 | 3 min read
Gilead’s experimental antiviral drug shortened the average time it took COVID-19 patients to recover in a NIAID-sponsored trial. There was weak evidence that it also helped reduce deaths.
chloroquine hydroxychloroquine covid-19 coronavirus sars-cov-2 malaria antimalarial antiviral
Chloroquine for COVID-19: Cutting Through the Hype
Chris Baraniuk | Mar 20, 2020 | 4 min read
President Donald Trump has touted the drug as a treatment but scientists still don’t know for sure that it is effective in patients. A number of clinical trials aim to find out.
Remdesivir Works Against Coronaviruses in the Lab
Abby Olena, PhD | Mar 20, 2020 | 4 min read
The antiviral disables RNA replication machinery in MERS and SARS viruses. Can it beat back SARS-CoV-2?
The Latest Drug Trials for Coronavirus
Ashley Yeager | Feb 18, 2020 | 2 min read
Under careful watch of the World Health Organization, doctors will test a range of COVID-19 therapies, including HIV and flu antivirals, blood plasma infusions, and traditional Chinese medicines.
Flu and HIV Drugs Show Efficacy Against Coronavirus
Catherine Offord | Feb 3, 2020 | 2 min read
Combining the medications improved conditions in patients with severe 2019-nCoV infections, say doctors in Thailand.
Novel DNA-Sensing Pathway Found in Human Cells, Absent in Mice
Catherine Offord | Jan 24, 2020 | 4 min read
This previously unknown mechanism for spotting foreign genetic material in the cytoplasm launches antiviral defenses even when the well-known immune mediator STING is absent.
flu influenza xofluza virus drug-resistant baloxavir
Drug-Resistant Flu Can Emerge After Patients Take Antiviral
Kerry Grens | Nov 26, 2019 | 2 min read
Roughly a quarter of 38 viral samples from people treated with Xofluza had mutations in their genomes that made the pathogens less susceptible to the drug.
Two Experimental Drugs Effective at Treating Ebola
Catherine Offord | Aug 13, 2019 | 2 min read
REGN-EB3 and mAb114 reduced mortality in a clinical trial carried out during the ongoing outbreak in Democratic Republic of Congo.
Many Non-Antibiotic Drugs Affect Gut Bacteria
Catherine Offord | Mar 19, 2018 | 2 min read
A new study finds that more than 200 human-targeted, non-antibiotic drugs inhibit the growth of bacterial species that make up part of the human microbiome.
ADVERTISEMENT